CDNA clone-launched platform for high-yield production of inactivated zika virus
AssigneeBoard of Regents, The University of Texas System
InventorsXuping Xie, Chao Shan, Pei-Yong Shi
Life of this patent
Estimating the term…
Abstract
The invention generally relates to the development of variant Zika strains, cDNA clones and mRNA transcripts that contain specific mutations in the Zika ORF, and methods for producing high yields of Zika viruses (“ZIKVs”) using these variant cDNA clones, transcripts and strains. The produced ZIKVs can be used for the manufacture of purified inactivated vaccines (PIVs), which may be useful for treating ZIKV-related diseases and for providing immunoprotection against ZIKV.
Claims20
A variant Zika virus (ZIKV) cDNA clone, RNA transcript of the cDNA clone, or variant ZIKV strain which has been mutated to introduce at least one substitution mutation in at least one of the encoded ZIKV proteins, wherein said at least one substitution mutation comprises one or more of the following:
- NS1 K265E, prM H83R and NS3 S356F.
A variant ZIKV cDNA clone, RNA transcript of the cDNA clone, or variant ZIKV strain comprising a substitution mutation corresponding to A3282G in the ZIKV genome, wherein the A3282G substitution results in a K265E substitution in the NS1 protein upon expression of the cDNA clone, RNA transcript or strain.
Dependencies are inferred from the claim text.